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Introduction
Primary graft dysfunction (PGD), the clinical manifestation of  lung transplant ischemia-reperfusion inju-
ry, affects over 50% of  lung recipients within the first 72 hours and is the predominant cause of  short-
term mortality, as well as chronic lung allograft rejection (1, 2). Neutrophils are not only the histologi-
cal hallmarks of  transplant ischemia-reperfusion injury, but they also drive its pathogenesis (3, 4). While 
neutrophil depletion can ameliorate PGD, it is not clinically feasible, given their importance in patho-
gen clearance. We and others have recently demonstrated that donor human (CD14loCD16hi) and murine 
(CX3CR1+Ly6CloCCR2–) nonclassical monocytes (NCM) retained in the vascular space of  the donor lungs 
recruit neutrophils to transplanted lungs through the release of  CXCL2 (5–8). Genetic and pharmacolog-
ical depletion of  NCM attenuates neutrophil recruitment and prevents PGD. Host-origin Ly6ChiCCR2+ 
classical monocytes (CM) are recruited from the spleen to the transplanted lungs, and complementary to 
the NCM, they mediate extravasation of  the recruited neutrophils into the interstitial space by permeabiliz-
ing the endothelium through the secretion of  IL-1β (9). Therefore, both donor NCM and recipient CM are 
necessary for neutrophil trafficking into reperfused lung grafts (2).
Primary graft dysfunction (PGD) is the predominant cause of early graft loss following lung 
transplantation. We recently demonstrated that donor pulmonary intravascular nonclassical 
monocytes (NCM) initiate neutrophil recruitment. Simultaneously, host-origin classical monocytes 
(CM) permeabilize the vascular endothelium to allow neutrophil extravasation necessary for PGD. 
Here, we show that a CCL2-CCR2 axis is necessary for CM recruitment. Surprisingly, although 
intravital imaging and multichannel flow cytometry revealed that depletion of donor NCM 
abrogated CM recruitment, single cell RNA sequencing identified donor alveolar macrophages (AM) 
as predominant CCL2 secretors. Unbiased transcriptomic analysis of murine tissues combined 
with murine KOs and chimeras indicated that IL-1β production by donor NCM was responsible for 
the early activation of AM and CCL2 release. IL-1β production by NCM was NLRP3 inflammasome 
dependent and inhibited by treatment with a clinically approved sulphonylurea. Production of 
CCL2 in the donor AM occurred through IL-1R–dependent activation of the PKC and NF-κB pathway. 
Accordingly, we show that IL-1β–dependent paracrine interaction between donor NCM and AM leads 
to recruitment of recipient CM necessary for PGD. Since depletion of donor NCM, IL-1β, or IL-1R 
antagonism and inflammasome inhibition abrogated recruitment of CM and PGD and are feasible 
using FDA-approved compounds, our findings may have potential for clinical translation.
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CM originate in the BM but reside in the spleen, which serves as a monocyte reservoir for rapid deploy-
ment of  the CM to the site of  injury (10). Indeed, the chemokine receptor CCR2, a ligand for CCL2 
(also known as monocyte chemoattractant protein 1; MCP-1), has been shown to promote recruitment 
of  CM to the site of  injury (11–13). However, mechanisms that drive the recruitment of  CM into lung 
grafts remain unknown. The characterization of  mechanisms of  monocyte trafficking into the transplanted 
lung has the potential to not only ameliorate transplant ischemia-reperfusion injury by reducing neutrophil 
extravasation, but also to reduce long-term allograft rejection and fibrosis by inhibiting development of  
monocyte-derived profibrotic macrophages (14). Alveolar macrophages (AM) are long-lived cells found in 
the alveoli and airways, and they have a range of  functions in the lungs, including maintenance of  homoeo-
stasis and immune surveillance (15). AM induced early reperfusion injury, and neutrophil recruitment has 
been postulated and verified by several groups (5, 16).
Using the vascularized murine lung transplant model, as well as tissues from human transplant recip-
ients, we found in the present report that donor AM were the predominant secretors of  CCL2, which was 
necessary for recruitment of  CM. Intriguingly, 2-photon imaging and multichannel flow cytometry demon-
strated that depletion of  donor NCM attenuated recruitment of  CM to the transplanted lungs. Unbiased 
transcriptomic profiling revealed that donor NCM produced IL-1β, while AM produced CCL2. Donor 
NCM, through the release of  IL-1β, activated donor AM, which was responsible for the secretion of  CCL2, 
recruitment of  CM, and development of  PGD. Pharmacological and genetic inhibition of  the NLRP3 
inflammasome prevented IL-1β release and the activation of  donor AM, which prevented CM recruitment 
and development of  PGD. Thus, we demonstrated that crosstalk between donor NCM and donor AM 
drives the recruitment of  recipient splenic CM. Our findings have potential implications in the design of  
clinically relevant interventions to attenuate PGD and acute and delayed lung allograft dysfunction.
Results
Depletion of  donor NCM suppresses recruitment of  recipient splenic CM. Donor origin intravascular pulmonary 
NCM produce CXCL2 and recruit recipient neutrophils into the allograft (6). CM are recruited from the 
host spleen immediately after reperfusion and mediate neutrophil extravasation into the transplanted lung 
by permeabilization of  the pulmonary endothelium through the production of  IL-1β (9). Host splenectomy 
abrogates recruitment of  the CM, neutrophil extravasation, and the development of  PGD (9). We found that 
anti-CCR2 treatment of  the recipients significantly attenuated the number of  CM recruited to the transplant-
ed lung (Figure 1A). Since anti-CCR2 antibody treatment could potentially lead to the depletion of  the recip-
ient CM, we used Ccr2–/– recipient mice and, similarly, found a decrease in the number of  CM in the lung 
allograft (Figure 1B). However, when we analyzed the levels of  CM in the spleen of  Ccr2–/– recipients, we 
found monocytopenia (Figure 1C), which could potentially explain the reduction in the CM recruitment to 
the lung allograft in these recipients (Figure 1B). Therefore, we neutralized the chemokine ligand for CCR2 
(CCL2) in the recipients by injecting anti-CCL2 antibodies (17) prior to transplantation and found a signifi-
cant reduction in the CM influx into the transplanted lung (Figure 1D). Next, since we described that donor 
NCM initiate neutrophil recruitment (6), we hypothesized that they also played a role in the recruitment 
of  recipient CM from the spleen. Indeed, when we depleted donor NCM, either genetically using Nr4a1–/– 
donor lungs (Figure 2, A–D, and Supplemental Videos 1 and 2; supplemental material available online with 
this article; https://doi.org/10.1172/jci.insight.147282DS1) or pharmacologically using i.v. clodronate lipo-
somes (Clo-lip) treatment in the donors (Figure 2D, Supplemental Figure 1, and Supplemental Videos 3 and 
4), the recruitment of  CM to the reperfused lungs was attenuated based on both 2-photon imaging (Figure 2, 
A–C, and Supplemental Figure 1) and multichannel flow cytometry (Figure 2D). Of note, the extravasation 
of  recruited CM was not impacted by the presence of  donor NCM (Figure 2C). Accordingly, we explored 
whether donor NCM produced CCL2 to recruit recipient splenic CM. Surprisingly, secondary analysis of  
our previously published RNA sequencing (RNA-seq) data set (6) (Figure 2E), as well as quantitative PCR 
(qPCR) of  donor human and murine NCM isolated immediately following reperfusion (Figure 2F), revealed 
that donor NCM were not the source of  CCL2 secretion. Nevertheless, depletion of  donor NCM led to a 
decrease in the blood CCL2 levels following murine lung transplantation (Figure 2G). Therefore, we hypoth-
esized that donor NCM led to the secretion of  CCL2 in the donor lung through a secondary mechanism.
Depletion of  donor AM suppresses recruitment of  recipient CM to the transplanted lung and neutrophil extravasa-
tion. Donor lungs are rapidly repopulated with recipient myeloid cells after transplantation, and 24 hours 
after transplant, only AM — and a few interstitial macrophages (IM) and NCM — remain of  donor origin 
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(Figure 3A and Supplemental Figure 2). Using the unbiased approach of  transcriptional profiling with single 
cell RNA-seq (scRNA-seq), we compared lung myeloid cells from naive and donor lungs collected 24 hours 
after transplant. We found that Ccl2 mRNA was mainly expressed by donor AM after lung transplantation 
(Figure 3B). We confirmed that donor AM are the dominant secretors of  CCL2 following lung transplanta-
tion by using donor lungs from a reporter Ccl2–red fluorescent protein (Ccl2-rfp) mouse (18). Transplantation 
of  donor Ccl2-rfp lungs into WT recipients allowed determination of  CCL2 increase in the various donor 
cell lineages through the expression of  RFP by flow cytometry. Following transplantation, we found that 
donor AM (and, to a much lesser extent, IM) are the predominant secretors of  CCL2, as determined by an 
increase in the percentage of  RFP-expressing cells (Figure 3C and Supplemental Figure 3). We confirmed 
the increase in Ccl2 transcription in donor AM by secondary analysis of  our previously published RNA-seq 
data set (19) (Figure 3D), as well as qPCR of  donor human and murine AM isolated immediately following 
reperfusion (Figure 3E). To causally link CCL2 secretion by AM-to-CM recruitment, we depleted donor 
AM using Clo-lip (16) prior to transplantation and found a significant decrease in the recruitment of  CM, 
as well as neutrophil extravasation, following transplantation (Figure 3, F and G). Since pharmacological 
depletion of  donor AM can induce inflammation through cell death, we developed a conditional KO of  
Ccl2 in the donor AM by crossing Cd169Cre and Ccl2-rfpfl/fl mice (20). Donor lungs from Cd169CreCcl2-rfpfl/fl mice 
revealed lack of  CCL2 production in the donor AM, reduction in CCL2 levels in pulmonary veins, and sig-
nificantly decreased recruitment of  recipient CM (Figure 3, H–J). Together, these data indicate that donor 
AM play a crucial role in the recruitment of  recipient CM.
CCL2 production by donor AM is dependent on IL-1β. Previous reports suggest that IL-1β can regulate the 
expression of  CCL2 (21); therefore, we investigated whether AM expressed CCL2 in response to IL-1β 
Figure 1. The CCL2-CCR2 axis is necessary for recipient classical monocytes (CM) recruitment to the allograft. (A) 
Flow cytometry quantification of CM (live CD45+Ly6G–NK1.1–CD11b+SiglecF–CD24–Ly6Chi) recruited into the allograft after 
treatment of recipients with i.v. IgG isotype or anti-CCR2 antibodies (n = 5). (B) Flow cytometry quantification of CM as 
described in A, recruited into the allograft using WT or Ccr2–/– recipient mice (n = 5). (C) Flow cytometry quantification 
of CM (live CD45+Ly6G–NK1.1–CD19–CD11b+CF4/80–CD11c–Ly6Chi) in spleens of WT or Ccr2–/– recipients after lung trans-
plant (n = 5–6). (D) Flow cytometry quantification of CM as described in A, recruited into the allograft after treatment 
of recipients with i.v. IgG isotype or anti-CCL2 antibodies in recipient mice (n = 3). Graphs show means ± SD. Graphs 
were analyzed by unpaired Student’s t test. ***P < 0.001; ****P < 0.0001.
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both in vitro and in vivo. We found that AM freshly isolated from WT mice, but not Il1r–/– mice, expressed 
Ccl2 in vitro when stimulated with IL-1β (Figure 4A). Binding of  IL-1β to the IL-1R leads to cell signaling 
transduction events that culminate with NF-κB activation via PI3K- or PKC-dependent pathways (22–24). 
To determine whether CCL2 was dependent of  PI3K- or PKC-dependent pathways, we treated freshly 
isolated AM with IL-1β in the presence or absence of  specific inhibitors. Treatment with the PI3K inhibitor 
LY294002 did not alter IL-1β–induced Ccl2 expression in AM, but Bisindolylmaleimide (PKC inhibitor) 
or BAY11-7082 (NF-κB inhibitor) both strongly suppressed Ccl2 production (Figure 4B). Next, to deter-
mine the role of  IL-1β in activating AM in vivo, we isolated AM from WT donor lungs transplanted into 
WT recipients and found increased Ccl2 expression, which was significantly blunted in AM isolated from 
Il1r–/– donor mice transplanted into WT recipients (Figure 4C). We confirmed this observation by treating 
the donors with anakinra, an IL-1R inhibitor approved by the US Food and Drug administration (FDA) 
for human use. Donors treated with anakinra showed significantly decreased recruitment of  CM at 2, 12, 
and 24 hours following transplantation (Figure 4D). Treatment of  recipients with neutralizing antibodies 
against IL-1β revealed similar results at identical time points (Figure 4D).
NLRP3 inflammasome dependent IL-1β release from donor NCM activates donor AM. The above data indicate that 
both donor NCM and donor AM are necessary for the recruitment of recipient CM, although only donor AM 
Figure 2. Depletion of donor nonclassical monocytes (NCM) suppresses the recruitment of recipient splenic classical monocytes (CM) to the allograft. (A–C) 
Intravital 2-photon imaging between 2 and 2.5 hours after reperfusion. (A) Representative still images of WT and Nr4a1–/– donor grafts. Green, CCR2-GFP; red, 
Qdot655 blood vessels. (B and C) CCR2-GFP cell density (B) and percent of extravasated CCR2-GFP (C) calculated using NIH ImageJ software in WT and Nr4a1–/– 
mice grafts after transplantation. (D) Flow cytometry quantification of CM (live CD45+Ly6G–NK1.1–CD11b+SiglecF–CD24–Ly6Chi) recruited into the allograft after 
i.v. injection of PBS liposomes (PBS-lip) or clodronate liposomes (Clo-lip) in donor mice or using WT or Nr4a1–/– as donor lungs (n = 5). (E) Normalized counts per 
minute (CPM) of Ccl2 in sorted donor NCM isolated from allografts 2 and 24 hours after transplant. (F) Relative Ccl2 mRNA levels of human and mouse NCM iso-
lated before and after reperfusion (n = 3). (G) CCL2 levels in blood from mice in D (n = 5). Graphs show means ± SD. The graph in B was analyzed by 2-way ANOVA 
followed by Sidak’s post hoc test. *WT versus Nr4a1–/–; #WT 2 hours versus WT 2.5 hours. The graph in E was analyzed by 1-way ANOVA followed by Tukey’s post 
hoc test. Graphs in C, D, F, and G were analyzed by unpaired Student’s t test. #P < 0.05, **P < 0.01; ***P < 0.001; ****P < 0.0001. Scale bar: 50 μm.
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produced the chemokine CCL2 when stimulated by IL-1β. To determine whether donor NCM produce IL-1β, 
we analyzed the scRNA-seq from naive lungs and pulmonary grafts 24 hours after transplantation. We found 
that, in addition to NCM, neutrophils also express increased levels of IL-1β mRNA after lung transplantation 
(Figure 5A). To interrogate the role of neutrophils in IL-1β secretion, we depleted recipient neutrophils by 
administering anti-Ly6G antibodies (25) and analyzed Ccl2 levels in donor AM following transplantation. We 
Figure 3. Depletion of donor alveolar macrophages (AM) suppresses recruitment of recipient classical monocytes (CM) to the transplanted lung. (A) Flow 
cytometry showing percentage of cells of donor (CD45.1) and recipient (CD45.2) origin in the allograft 24 hours after transplantation. Neutrophils were gated as 
live CD45+Ly6G+CD11b+CD24+SSChi; AM were gated as live CD45+Ly6G–NK1.1–SiglecF+CD64+CD11c+; CM were gated as live CD45+Ly6G–NK1.1–CD11b+SiglecF–CD24–Ly6Chi; 
NCM were gated as live CD45+Ly6G–NK1.1–CD11b+SiglecF–CD24–Ly6Clo (n = 3); and interstitial macrophages (IM) were gated as live CD45+Ly6G–NK1.1–CD11b+MHC 
II+CD11c+CD64+CD24− (n = 3–6). (B) UMAP plot (left) and feature plots (middle and right) showing specific cell populations and expression of Ccl2 in naive lungs and 
in allografts (Allo) 24 hours after transplant. (C) Flow cytometry showing percentage of RFP+ cells in lung allografts after transplantation of donor Ccl2-rfp grafts 
into WT recipient. AM and NCM were gated as in A. (D) Normalized counts per minute (CPM) of Ccl2 in sorted mouse AM isolated from allografts 2 hours after 
transplant (n = 4). (E) Relative Ccl2 mRNA levels of human and mouse AM isolated before and after reperfusion (n = 3–5). (F) Flow cytometry quantification of CM 
gated as in A, recruited into the allograft after intratracheal administration of PBS liposomes (PBS-lip) or clodronate liposomes (Clo-lip) in the donor mice (n = 4). 
(G) Flow cytometry quantification of extravasated neutrophils in the allograft gated as in A, after intratracheal administration of PBS-lip or Clo-lip in donor mice (n 
= 3). (H) Relative Ccl2 mRNA levels in AM isolated from WT, Cd169Cre, Ccl-rfpfl/fl, and Cd169CreCcl2-rfpfl/fl allografts and compared with naive AM (n = 5). (I) Blood CCL2 
levels after transplant combinations described in H (n = 5). (J) Flow cytometry quantification of CM gated as in A, after transplant combinations described in H (n 
= 5). Graphs show means ± SD. Graphs in C–G were analyzed by unpaired Student’s t test. Graphs in H–J were analyzed by 1-way ANOVA followed by Tukey’s post 
hoc test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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found that neutrophil depletion did not blunt the increased Ccl2 expression in donor AM following reperfusion 
(Figure 5B). These results are indicative of a role for NCM in IL-1β production after lung transplant. We found 
increased Il1β mRNA in donor murine NCM isolated immediately following reperfusion by qPCR (Figure 
5C). Ccl2 expression in donor AM was abrogated after transplantation of Nr41a–/– donor lungs, indicating its 
dependence on IL-1β secretion by donor NCM (Figure 5D). Furthermore, recruitment of neutrophils and CM 
was an independent function of donor NCM, since administration of anti-CXCL2, which we have previously 
shown to abrogate neutrophil recruitment (6), did not change influx of recipient CM (Figure 5E).
The assembly of  the NLRP3 inflammasome leads to caspase 1–dependent release of  the IL-1β (26). 
Consistently, donor lungs from Nlrp3–/– mice showed reduced Ccl2 expression by donor AM, and CM and 
neutrophil recruitment into the lung allograft (Figure 6, A–C). CM recruitment was restored after recon-
stitution of  Nlrp3–/– donor lungs with WT NCM prior to transplantation (Figure 6B). To achieve clini-
cal relevance, we treated murine donors with glyburide, a sulfonylurea that strongly inhibits the NLRP3 
inflammasome (27). Treatment of  donor lungs with glyburide resulted in significantly attenuated CM and 
neutrophil recruitment, as well as neutrophil extravasation following transplantation (Figure 6, D–F).
Discussion
Inflammatory CCR2+ CM are recruited to the lung in response to injury, where they have diverse functions. 
Recruitment of these CM is a critical step in the development of lung transplantation ischemia-reperfusion 
injury (2, 9). CM facilitate extravasation of neutrophils into reperfused lungs and are central to the pathogenesis 
Figure 4. IL-1β is necessary for donor alveolar macrophages (AM) to produce CCL2. (A) AM were isolated from WT 
or Il1r–/– mice and incubated in vitro with PBS or 1 ng/μL of mouse recombinant IL-1β. Ccl2 mRNA expression was 
measured by qPCR 24 hours after incubation (n = 6–8). (B) AM isolated from WT mice were incubated for 30 minutes in 
vitro with DMSO (control), 50 μM LY294002 (LY), 10 μM Bisindolylmaleimide-I (Bis), or 1 μM BAY11-7082 before adding 
1 ng/μL of mouse recombinant IL-1β. Ccl2 mRNA expression was measured by qPCR 24 hours after incubation (n = 
3–7). (C) Donor AM were isolated from WT or Il1r–/– allografts 24 hours after transplant, and Ccl2 mRNA expression was 
measured by qPCR (n = 4–5). (D) Flow cytometry quantification of CM (live CD45+Ly6G–NK1.1–CD11b+SiglecF–CD24–Ly-
6Chi) from allografts harvested at the indicated times from experiments in which donor lungs were treated with PBS or 
anakinra, or in which recipients were treated with isotype control and anti–IL-1β antibody (n = 3 per group). Graphs show 
means ± SD. Graphs in A–C were analyzed by unpaired Student’s t test. Graph in D was analyzed by 2-way ANOVA, fol-
lowed by Sidak’s post hoc test. *PBS versus anakinra; #isotype versus anti–IL-1β antibody. *P < 0.05; **P < 0.01; ***P < 
0.001; ****P < 0.0001; ###P < 0.001; ####P < 0.0001.
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of PGD (3). In addition to PGD, they have been shown to play a crucial role in the development of alloim-
munity (13). CCR2+ CM also have the ability to differentiate into profibrotic AM that may drive lung fibrosis 
(14). The inflammatory monocytes originate in the BM and migrate to the spleen, where they are stored for 
rapid deployment (10). While the egress of CM from the BM has been shown to be dependent on the expres-
sion of CCR2 (12, 28), the ligand CCL2 (also known as MCP-1) is necessary for their migration to the site of  
lung inflammation (29). These observations may be more generalizable, since CCR2+ monocytes promote the 
transendothelial migration of neutrophils in murine models of arthritis (30). Reports using Ccr2-deficient mice 
have also demonstrated that CCR2 signaling contributes to myocardial, renal, and cerebral ischemia-reperfusion 
injury (12, 18). Therefore, inhibiting the migration of CM into the transplanted lungs offers several benefits, such 
as amelioration of ischemia-reperfusion injury and posttransplant allograft dysfunction.
We have previously shown that donor origin NCM retained in the pulmonary vasculature play important 
roles in the recruitment of  neutrophils. Depletion of  donor NCM not only attenuated recruitment of  recipient 
neutrophils, but also of  recipient-derived CM (Figure 2). Because the recruitment of  CM was dependent on 
CCL2, we hypothesized that, in addition to secreting the neutrophil chemoattractant CXCL2, donor NCM 
also released CCL2. Surprisingly, we found that donor NCM did not upregulate CCL2; therefore, we turned 
to an unbiased transcriptomic approach that revealed that donor AM were the predominant sources of  Ccl2, 
an observation confirmed by the increase of  RFP in AM from Ccl2-rfp donor lungs and direct Ccl2 measure-
ment in donor AM, as well as genetic and pharmacologic depletion of  donor AM. While we also found 
some expression of  CCL2 in donor IM, these cells are few, as they are almost completely replaced by cells 
of  recipient origin by 24 hours after transplant. Furthermore, selective pharmacological depletion of  AM or 
conditional deletion of  Ccl2 in the AM, using Cd169CreCcl2-rfpfl/fl donor mice, led to a significant reduction of  
Ccl2 levels in the recipient, reduced CM recruitment, and protection from PGD.
IL-1β is a proinflammatory cytokine implicated in a wide range of  physiological processes, including 
the initiation and orchestration of  the inflammatory response to pathological inflammatory conditions (31). 
Figure 5. Nonclassical monocyte–derived (NCM-derived) IL-1β promotes CCL2 production by donor alveolar macrophages (AM). (A) UMAP plot (left) and 
feature plots (middle and right) showing specific cell populations and expression of Il1β in naive lungs and in allografts (Allo) 24 hours after transplanta-
tion. (B) Ccl2 mRNA levels determined by qPCR in AM from the allograft after i.v. administration of IgG isotype or anti-Ly6G antibodies in recipient mice (n 
= 2–3). (C) Relative Il1β mRNA levels of mouse donor NCM isolated before and after reperfusion (n = 3–4). (D) Ccl2 mRNA levels determined by qPCR in AM 
isolated WT or Nr4a1–/– lung allografts 24 hours after transplantation (n = 4–6). (E) Flow cytometry quantification of CM (live CD45+Ly6G–NK1.1–CD11b+Si-
glecF–CD24–Ly6Chi) recruited into the allograft after treatment of recipients with i.v. IgG isotype or anti-CXCL2 antibodies (n = 5). Graphs show means ± SD. 
Graphs were analyzed by unpaired Student’s t test.*P < 0.05.
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IL-1β is crucial for a variety of  host responses to injury (32), including hepatic (33) and renal (34) isch-
emia-reperfusion injury. Elevated levels of  IL-1β in donor lungs undergoing ex vivo lung perfusion have been 
proposed as a biomarker for PGD following transplantation (35–37) and were associated with increased 
alveolar neutrophils in a murine model of  ischemia-reperfusion induced by hilar clamping (38). We found 
that AM produced CCL2 in response to IL-1β through a PKC- and NF-κB–dependent but PI3K-indepen-
dent pathway. However, we recognize that in the lung, CCL2 can be produced by both stromal cells and 
hematopoietic cells (39, 40). However, our data suggest that stromal cells may not play an eminent role in 
CCL2 release in our lung transplant model.
The secretion of  IL-1β from NCM initiated a signaling cascade that promoted the release of  CCL2 from 
donor AM and the recruitment of  CM. However, it is possible that cells of  recipient origin may also contrib-
ute to IL-1β production. To this end, the transcriptional analysis revealed that recipient neutrophils also upreg-
ulated Il1β. However, depletion of  neutrophils, at least at the initial time points following transplantation, did 
not alter the Ccl2 expression in donor AM. We, nevertheless, recognize that it is possible that neutrophils can 
perpetuate the activation of  donor AM after they are recruited to the allograft by donor NCM. In the clinical 
context, differentiating the relative contribution of  donor NCM and recipient neutrophils in IL-1β production 
may not be relevant since neutrophil recruitment is dependent on donor NCM and can be abrogated by tar-
geting the donor NCM prior to transplantation. Our prior studies have also shown that CCR2+ monocytes can 
produce large amounts of  IL-1β after being recruited to the lung grafts (9). We postulate that the IL-1β derived 
from the recruited CCR2+ CM can also create a self-propagating circuit to recruit more CM through ongoing 
activation of  donor AM. Since these recruited CM also contribute to the development of  alloimmunity (13), 
our studies may provide an immunological link between severe forms of  PGD and chronic allograft rejection 
Figure 6. Nonclassical monocytes (NCM) produce IL-1β via NLRP3 inflammasome activation. (A) Ccl2 mRNA levels deter-
mined by qPCR in AM isolated from WT or Nlrp3–/– lung allografts 24 hours after transplantation (n = 3). (B) Flow cytometry 
quantification of CM (live CD45+Ly6G–NK1.1–CD11b+SiglecF–CD24–Ly6Chi) recruited to allografts from WT, Nlrp3–/–, or Nlrp3–/– 
reconstituted with WT NCM donor mice (n = 3–4). (C) Flow cytometry quantification of neutrophils (live CD45+Ly6G+CD11b+C-
D24+SSChi) recruited into WT of Nlrp3–/– allografts 24 hours after transplantation (n = 5–7). (D) Flow cytometry quantification 
of CM gated as in C, recruited into the allograft after donor treatment with 50 μg/g body weight glyburide (n = 4). (E) Flow 
cytometry quantification of neutrophils gated as in B, recruited into the allograft after i.p. administration glyburide in the 
donor mice (n = 4–7). (F) Flow cytometry quantification of extravasated neutrophils in the allograft gated as in B, after 
donor treatment with glyburide (n = 4). Graphs show means ± SD. Graph in C was analyzed by 1-way ANOVA, followed by 
Tukey’s post hoc test. All other graphs were analyzed by unpaired Student’s t test. *P < 0.05; ***P < 0.001; ****P < 0.0001.
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(1, 20). Our unbiased transcriptomic analysis combined with genetic loss- and gain-of-function experiments in 
a clinically relevant murine model of  lung transplantation show causality between IL-1β secretion by donor 
NCM and activation of  AM, while indicating that any contribution of  IL-1β by other myeloid cells is down-
stream of donor NCM. Collectively, our previously published work (6, 9) and the current study demonstrate 
that donor NCM serve a dual role in recruiting host neutrophils, as well as CM. The recruitment of  host neu-
trophils by donor NCM occurs directly through MyD88/TRIF-dependent secretion of  CXCL2 (6). However, 
the recruitment of  host CM occurs indirectly by donor NCM-dependent production of  CCL2 by donor AM. 
Recruitment of  neutrophil and CM are independent of  each other, since neutrophil depletion did not alter 
CCL2 levels and neutralization of  CXCL2 did not reduce CM recruitment.
IL-1β is produced as an inactive 31 kDA precursor, pro–IL-1β, and processing and secretion of biologi-
cally active IL-1β is inflammasome dependent (41, 42). The best characterized inflammasome is formed by 
the cytosolic NLRP3 (43). Using single cell transcriptomic profiling, we observed that Il1β is upregulated in 
donor NCM following transplantation. Causal studies in this report show that the NLRP3 inflammasome is 
responsible for the NCM-dependent activation of the donor AM, leading to the secretion of CCL2. Although 
our results using the reconstitution of genetically deficient mice are compelling, it is also possible that neutro-
phil-derived serine proteases — including proteinase 3 (PR3), elastase, and cathepsin-G — can cleave secreted 
pro–IL-1β (32, 44, 45), or that other known inflammasomes such as NLRP1, NLRC4, and absent in melanoma 
2 (AIM2) (46) lead to the production of IL-1β from the NCM (47–55). Models described in our report could be 
used for future studies to determine the role of these alternate mechanisms, as well as activation of downstream 
NLRP3 inflammasome proteins in NCM by using NCM from Asc−/− and Caspase-1−/− mice (48, 50–54).
The findings in this study are particularly important, since they identify common pathways to attenuate 
the recruitment of  damaging neutrophils as well as the recruitment of  CM. Depletion of  donor NCM by 
agents such as bisphosphonates has the potential for not only preventing neutrophil recruitment, but also 
CM. Clodronate, a first-generation bisphonate, is approved for human use in Europe and Canada. Alterna-
tively, IL-1β–IL-1R interactions could be targeted therapeutically, as we described with the use of  anakinra 
(IL-1R inhibitor) and neutralizing antibodies against IL-1β, to serve the dual purpose of  not only pre-
serving endothelial integrity (9), but also attenuating the recruitment of  inflammatory splenic monocytes. 
NLRP3 inflammasome inhibition is another alternative strategy to abrogate the interaction between the 
NCM and AM. Our experiments using the inflammasome inhibitor glyburide are attractive, as it should be 
feasible to treat the donor lung prior to transplant to avoid toxicity in the recipient. Since glyburide is FDA 
approved, positive findings could be potentially translated to human lung transplantation.
In this report, wherever possible, we complemented our genetic studies in mice with preclinical studies using 
pharmacologic agents. We perform detailed analyses of small biopsies of tissues from the donor lung obtained 
in the operating room before and after reperfusion to confirm the relevance of our findings for our patients. We 
have used both allogeneic and syngeneic models in our study. However, in the majority of the experiments, we 
have used allogeneic murine transplants, since they are more relevant to the clinical transplantation. Furthermore, 
while we acknowledge that allogeneic transplants induce adaptive immunity, the goal of the present study was 
not to study the adaptive immune response. We have previously shown that allogeneic and syngeneic murine lung 
transplants are comparable when studying ischemia-reperfusion injury/PGD or neutrophil and monocyte traf-
ficking (6, 9). Our studies also show a paracrine signaling between donor cells, resident intravascular monocytes 
and tissue-resident extravascular macrophages, to recruit inflammatory monocytes from the spleen. This com-
plex interplay between the donor and recipient cells is exciting, since drugs inhibiting these pathways are already 
approved for use in humans. Furthermore, since therapies targeting signaling in these donor cells could be poten-
tially administered to donor lungs prior to transplantation, toxicity to the recipient can be minimized. In sum-
mary, we provide evidence that IL-1β–dependent activation of donor AM by donor NCM leads to recruitment 
of host CM, which are responsible for neutrophil extravasation and pathogenesis of PGD. Since inflammasome 
inhibition, depletion of donor NCM, IL-1β, or IL-1R antagonism abrogate recruitment of CM, as well as PGD, 
and are feasible using FDA-approved compounds, our findings may have potential for clinical translation.
Methods
Human samples
Lung graft samples were obtained both before and after reperfusion. Prereperfusion samples were obtained 
at the conclusion of cold ischemic storage (defined as the period between cooling of organs inside the donor 
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to extraction of the organs from the cold storage transport medium for implantation into the recipient). Post-
reperfusion samples were obtained after 15 minutes of reperfusion. Donor NCM were identified from fresh 
specimens using multicolor flow cytometry, using our previously described protocols (16), and were isolated 15 
minutes following reperfusion. Bronchoscopic bronchoalveolar lavage fluid (BALF) was used to collect donor 
AM. Briefly, BALF was obtained in the times above indicated, centrifuged (10 minutes, 400g, 4°C), and RBC 
lysed, and AM were collected. A total of 7 lung grafts were studied.
Mice and procedures
Mice. Male WT C57BL/6J (B6), BALB/c, BALB/c 45.1, Ccr2–/–, Ccr2-gfp, Nr4a1–/–, Ccl2-rfpfl/fl, Cd169Cre, Il1r–/–, 
and Nlrp3–/– mice were obtained from The Jackson Laboratory. Anakirna (100 μg/g body weight, Swedish 
Orphan Biovitrum) and anti–IL-1β (50 μg/g body weight, clone AF-401, R&D Systems) were used for IL-1β–
IL-1R antagonism. Donors were treated with glyburide (50 μg/g body weight, i.p., MilliporeSigma) for 3 
days before lung harvest. We used the dose of  glyburide of  50 μg/g body weight according to the published 
literature; prior studies have used a broad range of  glyburide from 2.5 μg/g (56) to 500 μg/g (27). We opted 
for a dose that was in the mid-range, as shown in multiple prior reports (57, 58). All mice were maintained in 
a specific pathogen–free facility at the Center for Comparative Medicine at Northwestern University and used 
for the described experiments between the ages of  9–14 weeks and between 24–28 grams of  body weight. A 
total of  400 mice were used in these studies.
Mouse lung transplantation. Orthotopic murine left lung transplantation was performed as previously described 
(6). All lung transplants performed in this study were allogeneic (except for Figure 2A, which were syngeneic 
using B6 mice), using B6 and BALB/c background mice. Unless specified otherwise, lungs were harvest 24 
hours after transplantation. Briefly, donor mice were anesthetized with a mixture of xylazine (10 mg/kg, Akorn 
Pharmaceutical) and ketamine (100 mg/kg, Covetrus). Donor lungs were flushed through the pulmonary artery 
with 3 mL of saline solution, and the heart-lung block was excised and kept in cooled (4°C) preservative solu-
tion. The bronchus, pulmonary vein, and artery were dissected and prepared for anastomosis. A customized 
cuff made of a Teflon i.v. catheter was applied to the vascular structures and secured with a 10-0 nylon ligature. 
After placement of a microvessel clip on the bronchus to avoid airway infiltration with preservative solution, 
the graft was stored at 4°C for a period of 90–120 minutes prior to implantation. Recipient mice received s.c. 
buprenorphine (0.1 mg/kg) 30 minutes prior to the thoracic surgical incision and every 6 hours as needed after 
the transplant procedure. Recipient mice were intubated, and a left-sided thoracotomy was performed on each 
mouse within the third intercostal space. The recipient’s native lung was gently clamped and pulled out of the 
thoracic cavity. The space between the artery, the vein, and the bronchus was dissected separately. The artery 
and vein were temporarily occluded using 8-0 nylon ligatures. The anastomoses were completed by securing 
each cuff with 10-0 nylon ligatures. The 8-0 ligatures were released (first vein and then artery), and the lung was 
inflated. The chest incision was closed, and recipients were separated from the ventilator when spontaneous 
respiration resumed. No antibiotics or immunosuppressive agents were used postoperatively in any groups.
CCL2, CXCL2, and cell depletion. Clodronate-loaded liposomes and control phosphate-buffered saline lipo-
somes were purchased from Clodronateliposomes.com. At specific time points, mice were injected intratra-
cheally (50 L) or i.v. (200 L) with clodronate-loaded liposomes or control PBS-loaded liposomes to deplete 
AM or monocytes, respectively (59). Cytotoxic anti-CCR2 antibody (a gift from Steffen Jung, The Weizmann 
Institute of  Science, Israel) was used for selective depletion of  CCR2+ CM as previously described (50 μg 
i.v. 24 hours prior to lung transplant) (6). CCL2 antibody (50 μg/mouse, clone AF-479, R&D Systems) was 
injected i.v. to neutralize CCL2 (17). CXCL2 antibody (50 μg/mice, clone AF-452, R&D) was injected i.v. to 
neutralize CXCL2. Neutrophils were depleted by using Ly6G antibody (12.5 mg/Kg body weight, clone 1A8, 
BioLegend). Control mice were treated with the same amounts of  IgG isotype control antibodies (R&D).
NCM reconstitution. NCM were isolated as described before (6). Briefly, mouse lung tissue was digested, 
single cell suspensions were prepared, and NCM were sorted from WT mice using a FACSARIA 4-Laser 
Sorter. For reconstitution of  Nlrp3–/– mice, 50,000–100,000 NCM were injected into Nlrp3–/– mice into the 
donor pulmonary artery of  the donor murine lungs ex vivo, immediately prior to implantation of  the lung.
Flow cytometry and sorting
Human and mouse lung and mouse spleen tissue were digested, and single cell suspensions were prepared 
as previously described (6, 9). Cell suspensions underwent RBC lysis using Pharm Lyse buffer (BD Biosci-
ences). Live/dead staining was performed in protein-free solution (HBSS) using fixable viability dye eFluor 
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506 (eBioscience), followed by incubation with FcR-blocking reagent (Miltenyi Biotec). Cells were then 
stained with the different antibodies (Table 1 and Table 2). NCM were sorted using a FACSARIA 4-Laser 
Sorter, and flow analysis of  fixed samples was performed on a BD FACS Symphony A5-Laser Analyzer at 
the Northwestern University Robert H. Lurie Comprehensive Cancer Center Flow Cytometry Core facility. 
Acquired data were analyzed with FlowJo v10.6 (FlowJo).
Two-photon microscopy
A custom built 2p microscope running ImageWarp acquisition software (A&B Software) was used for time-
lapse imaging. Mice were anesthetized with an i.p. injection of ketamine (50 mg/kg) and xylazine (10 mg/kg) 
and maintained with administration of half doses every hour through the imaging process. Mice were intubat-
ed orotracheally and ventilated with room air at a rate of 120 breaths/minute and with a tidal volume of 0.5 
mL. Left thoracotomy was performed to expose the left lung, and the lung was imaged using a custom-built 
chamber maintained at 37°C. Vetbond ring was used to attach the lung tissue to the bottom of the cover glass 
without direct pressure on the exposed lung. For time-lapse imaging of migration of CCR2+, we averaged 15 
video-rate frames (0.5 seconds per slice) during the acquisition to match the ventilator rate and minimize move-
ment artifacts. Each plane represents an image of 220 × 240 μm in the x and y dimensions. To visualize blood 
vessels, 20 μL of 655 nm nontargeted Qdots in 100 μL of PBS was injected i.v. prior to imaging (60–62). Two- 
photon microscopy images for Clo-lip experiments shown in Supplemental Figure 1 were acquired using a water 
immersion lens (Apo LWD 25× 1.10W DIC N2) on a Nikon A1R-MP+ multiphoton microscope system with 
a Coherent Chameleon Vision titanium sapphire laser. For each mouse, images of 512 × 512 μm in the x and y 
dimensions were acquired using an excitation wavelength tuned at 920 nm. To visualize blood vessels, 100 μL 
(5 mg/mL) of dextran tetramethylrhodamine in PBS were injected i.v. 5 minutes prior to imaging. Images were 
processed and analyzed using NIS-Elements NIS.ai (Nikon), Imaris (Bitplane), and NIH ImageJ software.
Secondary transcriptomic analysis
RNA-seq. RNA isolation and sequencing procedures are detailed in our previous manuscript (6). For all analyses, 
normalized tables of counts were generated from raw counts using the EdgR package (version 3.18.1). Filtering for 
low counts was performed by excluding genes, which have the expression from more than half of all the samples.
scRNA-seq
Single cell suspensions from naive lungs and lung grafts 24 hours after transplantation were prepared as described 
above for flow cytometry with slight modifications. Grafts were removed and digested with 3 mL dispase (Corn-
ing) with DNase I (MilliporeSigma) and were gently teased using forceps into small (1–2 mm) fragments, fol-
lowed by incubation at room temperature with gentle agitation for 30 minutes. The resulting suspension (in 
Table 1. Antibodies used for mouse flow cytometry and sorting
Antigen Clone Fluorochrome Manufacturer
CD24 M1/69 BUV496 BD Horizon
CD45 30-F11 APC-Cy7/APC BioLegend
CD11b M1/70 BUV737/APCCy7 BD Bioscience
MHCII M5/114.15.2 PerCPCy5 BioLegend
MHCII 2G9 BUV395 BD Bioscience
Ly6C HK 1.4 eFluor450 eBioscience
Ly6G 1A8 AF 700 BD Bioscience
NK1.1 PK136 PECF594/AF 700 BD Bioscience
CD64 X54-5/7.1 PE BioLegend
SiglecF E50-2440 APC/PECF594 BD Bioscience
CD11c HL3 PECy7 BD Bioscience
CD45.2 104 APC BD Bioscience
CD45.1 A20 FITC BD Bioscience
CD19 1D3 PECF594 BD Bioscience
F4/80 BM8 PE BioLegend
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DMEM + 5% FBS) was passed through 70 μm cell strainer; erythrocytes were lysed and filtered through 40 μm 
cell strainers. Cells were counted using acridine orange/propidium (AO/PI) and Cellometer K2 (Nexcelom), 
and cell viability exceeded 90%. Single cell 3’ RNA-Seq libraries were prepared using Chromium Single Cell 
V2 Reagent Kit and Controller (10x Genomics). Libraries were assessed for quality (TapeStation 4200, Agilent 
Technologies) and then sequenced on NextSeq 500 or HiSeq 4000 instruments (Illumina). Initial data processing 
was performed using the Cell Ranger version 2.0 pipeline (10x Genomics), and reads were mapped to mm10 
version of the mouse genome, Ensemble build 84. Downstream scRNA-seq analysis was performed using Seur-
at Package version 3.1.0 following the standard workflow posted on the Satija lab website (https://satijalab.
org/seurat/) (63). Specifically, SCTransform with an anchor-based integration approach was used to integrate 4 
different samples from 2 conditions. Cell types were identified using both manual annotations based on positive 
markers from FindAllMarkers function in Seruat pipeline and a supervised annotation tool, SingleR (64). The 
RNA-seq data can be found in the GEO repository (geo166679).
mRNA isolation and qPCR
Total RNA was extracted using miRNeasy Mini kit (Qiagen). cDNA was synthesized from 5–250 ng of total RNA 
by using a qScript cDNA Synthesis kit (Quanta Biosciences), and mRNA expression was determined by qPCR 
using iTaq Universal Probes Supermix (Bio-Rad). Relative expression of the transcripts was determined accord-
ing to the ΔΔCt method using actin or rpl19 as reference for normalization. The following primers were used 
for mouse samples: Ccl2-F, 5′ - GCATCCACGTGTTGGCTCA - 3′; Ccl2-R, 5′ - CTCCAGCCTACTCATTGG-
GATCA - 3′; β-actin–F, 5′ - CACCACACCTTCTACAATGA - 3′; β-actin–R, 5′ - GTCTCAAACATGATCTG-
GGT - 3′; Rpl19-F, 5′ - GAAATCGCCAATGCCAACTC - 3′; Rpl19-R, 5′ - CTTCAGGTACAGGCTGTGA-
TAC - 3′; Il1β-F, 5′ - GGCAGGCAGTATCACTCATT - 3′; and Il1β-R, 5′ - CCCAAGGCCACAGGTATTT 
- 3′. The following primers were used for human samples: Ccl2-F, 5′ - GCAGAAGTGGGTTCAGGATT - 3′; 
Ccl2-R, 5′ - GGGTAGAACTGTGGTTCAAGAG - 3′; β-actin–F, 5′ - GAAGTCCCTTGCCATCCTAAA; and 
β-actin–R, 5′ - GTCTCAAGTCAGTGTACAGGTAAG - 3′.
ELISA
Human and mouse CCL2 ELISA were performed using commercially available kits accordingly to the 
manufacturer’s instructions (Thermo Fisher Scientific; Human MCP1 ELISA kit [BMS281] and MCP-1 
Mouse ELISA Kit [BMS6005]).
Compartmental lung i.v. staining for neutrophils extravasation
I.v. and intratracheal procedures were performed utilizing an adaptation of  previously described methods 
(16, 19). Briefly, 6 μg of  APC-conjugated anti-CD45 in 100 μL of sterile PBS was injected i.v. and allowed to 
circulate for 3 minutes prior to euthanasia with an overdose of  Euthasol. Tracheostomy was performed. The 
vena cava was transected, and the right ventricle was flushed with 10 mL of HBSS to wash unbound antibody.
AM isolation and in vitro experiments
AM were isolated as previously described (16). Briefly, BALF from mice was obtained by performing a trache-
ostomy and lavaging with 2 mM EDTA-PBS solution (1 mL, 10 times per mouse), followed by centrifugation 
Table 2. Antibodies used for human flow cytometry and sorting
Antigen Clone Fluorochrome Manufacturer
CD45 HI30 BB515 BD Bioscience
CD14 MΦP9 PerCPCy5.5 BD Bioscience
HLA-DR L243 eF450 eBioscience
CD169 7-239 APC BioLegend
CD15 W6D3 A700 BioLegend
CD11b M1/70 APCCy7 BioLegend
CD16 3G8 PE BD Bioscience
CD163 GHI/61 PECF594 BD Bioscience
CD206 19.2 PECy7 eBioscience
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(10 minutes, 400g, 4°C) and RBC lysis. AM were resuspended in RPMI media supplemented with 10% FBS 
and antibiotics. Between 50,000 and 100,000 cells were plated in 24-well plates, allowed to rest for 2 hours, 
and incubated with 1 ng/μL mouse recombinant IL-1β (Thermo Fisher Scientific) in the absence or presence 
of  various antagonists (30 minutes before adding IL-1β): 50 μM LY294002 (Thermo Fisher Scientific), 10 
μM Bisindolylmaleimide I (Calbiochem), and 1 μM BAY11-7082 (Calbiochem). After 24 hours, media was 
discarded, AM was resuspended in RLT (Qiagen), and RNA was extracted as described above.
Statistics
Data analysis was performed using Prism 8 (GraphPad Software Inc.). Results are expressed as mean ± SD, 
and the n values for each data set are provided in the figure legends. Statistical significance was assessed by 
2-tailed Student’s t test, 1-way ANOVA followed by Tukey’s post hoc test, or 2-way ANOVA followed by 
Sidak’s post hoc test. A P value less than 0.05 was considered significant.
Study approval
All procedures were approved by the IACUC (IS00002248) at Northwestern University. Animals received 
humane care in compliance with the Guide for the Care and Use of  Laboratory Animals (National Academies 
Press, 2011) and the Principles of  Laboratory Animal Care formulated by the National Society for Medical 
Research. Human protocols were approved by the IRB at Northwestern University Feinberg School of  Medi-
cine (STU00106589). All study subjects provided written informed consent prior to participation in the study.
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